Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics (Nasdaq: AKBA) has announced the granting of stock options to eight newly-hired employees as part of their inducement award program. The grants, made on March 31, 2025, total 73,325 shares of common stock with an exercise price of $1.92 per share, matching the closing price on the grant date.
The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and was granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA) ha annunciato l'assegnazione di opzioni su azioni a otto nuovi dipendenti come parte del loro programma di premi di indennizzazione. Le concessioni, effettuate il 31 marzo 2025, ammontano a un totale di 73.325 azioni ordinarie con un prezzo di esercizio di 1,92 $ per azione, corrispondente al prezzo di chiusura nella data di concessione.
Le opzioni prevedono un programma di maturazione di quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura trimestralmente successivamente, a condizione di un impiego continuativo. Ogni opzione ha un termine di 10 anni ed è stata concessa in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA) ha anunciado la concesión de opciones sobre acciones a ocho nuevos empleados como parte de su programa de premios por inducimiento. Las concesiones, realizadas el 31 de marzo de 2025, suman un total de 73,325 acciones ordinarias con un precio de ejercicio de $1.92 por acción, igualando el precio de cierre en la fecha de concesión.
Las opciones cuentan con un calendario de adquisición de cuatro años, con el 25% adquiriéndose después del primer año y el 75% restante adquiriéndose trimestralmente a partir de entonces, condicionado a la continuidad del empleo. Cada opción tiene un plazo de 10 años y se otorgó de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA)는 유인 보상 프로그램의 일환으로 새로 채용된 직원 8명에게 주식 옵션을 부여했다고 발표했습니다. 2025년 3월 31일에 이루어진 이 부여는 총 73,325주의 보통주로, 행사 가격은 주당 1.92 달러로, 부여일의 종가와 일치합니다.
옵션은 4년의 베스팅 일정이 있으며, 첫 해에 25%가 베스팅되고 이후에는 나머지 75%가 분기별로 베스팅되며, 계속 고용되는 조건입니다. 각 옵션은 10년의 유효 기간을 가지며, Nasdaq 상장 규칙 5635(c)(4)에 따라 부여되었습니다.
Akebia Therapeutics (Nasdaq: AKBA) a annoncé l'octroi d'options d'achat d'actions à huit nouveaux employés dans le cadre de leur programme de récompenses d'incitation. Les attributions, effectuées le 31 mars 2025, totalisent 73 325 actions ordinaires avec un prix d'exercice de 1,92 $ par action, correspondant au prix de clôture à la date de l'attribution.
Les options comportent un calendrier d'acquisition de quatre ans, avec 25 % d'acquisition après la première année et les 75 % restants acquis trimestriellement par la suite, sous réserve d'un emploi continu. Chaque option a une durée de 10 ans et a été accordée conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA) hat die Gewährung von Aktienoptionen an acht neu eingestellte Mitarbeiter im Rahmen ihres Anreizprogramms bekannt gegeben. Die Zuteilungen, die am 31. März 2025 vorgenommen wurden, umfassen insgesamt 73.325 Stammaktien zu einem Ausübungspreis von 1,92 $ pro Aktie, was dem Schlusskurs am Zuteilungsdatum entspricht.
Die Optionen haben einen vierjährigen Vesting-Zeitplan, wobei 25% nach dem ersten Jahr und die verbleibenden 75% danach vierteljährlich fällig werden, vorausgesetzt, die Beschäftigung bleibt bestehen. Jede Option hat eine Laufzeit von 10 Jahren und wurde gemäß Nasdaq-Listing-Regel 5635(c)(4) gewährt.
- None.
- None.
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 73,325 shares of Akebia’s common stock on March 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
How many shares were granted in Akebia Therapeutics' (AKBA) March 2025 inducement grants?
What is the exercise price for AKBA's March 2025 inducement stock options?
What is the vesting schedule for Akebia's (AKBA) March 2025 inducement grants?
How long is the term of AKBA's March 2025 inducement stock options?
